LongevityET10
Single or box
Loading product
Loading product
Longevity · Research material
Package information
For product inquiries and additional information, contact lonestarpeptideco@gmail.com.
Compliance notice: For laboratory research use only. Not for human or veterinary use.
Product information is intended for laboratory, academic and commercial researchers aged 18 or over.
Material profile
A retro-inverso D-amino-acid peptide modelled on the FOXO4 interaction interface, designed as a protein-protein interaction probe for the FOXO4-p53 complex. Supplied as a lyophilized powder at 10 mg in one vial. A box of 10 is available as an optional package. The material is supplied for biochemical assay development and instrument calibration. For laboratory research use only. Not for human or veterinary use.
Catalog record
| Product | FOXO4-DRI — 10 mg |
|---|---|
| Catalog SKU | F410 |
| Compound | FOXO4-DRI |
| Appearance | Lyophilized white powder |
| Fill per vial | 10 mg |
| Storage condition | -20 °C, desiccated, protect from light |
Laboratory handling
Ships as a sealed lyophilized vial with cold-pack insulation. Keep at -20 degrees C in a dry, dark environment; this material is both hygroscopic and light-sensitive, and repeated freeze-thaw of the sealed vial should be avoided. Handling after receipt is the responsibility of the receiving laboratory under its own protocols.
Evidence first
This listing does not currently publish lot-specific analytical results. Request and review the applicable documentation before using the material in laboratory work.
Published literature
FOXO4-DRI is a D-retro-inverso peptide engineered to competitively disrupt the interaction between the FOXO4 forkhead-family protein and the p53 transactivation domain — an interaction senescent cells rely on to sequester p53 and evade apoptosis. In the foundational 2017 mouse study, researchers examined senescence, hepatic and renal function, and fur-density markers in naturally aged and doxorubicin-exposed (chemotoxicity) mouse models following systemic administration, reporting apoptosis selective to p16INK4a-positive senescent cells. Subsequent published work examined FOXO4-DRI's association with endothelial-cell and Leydig-cell senescence markers via the p53 signaling pathway in aged mice, and with senescent-cell clearance in expanded human chondrocyte cultures. FOXO4-DRI has not completed human clinical trials and holds no regulatory approval for any use.
Describes what the cited studies examined in the systems noted above — not a claim about outcomes for people. Not medical advice.
Product support
No downloadable certificate is currently attached to this listing. Email lonestarpeptideco@gmail.com if your laboratory requires lot-specific documentation for review.
Use the package selector to review the single-vial and box-of-10 formats, then use Email to inquire if you want to ask about that product.
The catalog storage condition is -20 °C, desiccated, protect from light. Follow the handling information on this page and your laboratory's written procedures.
No. It is presented only as laboratory research material and is not for human or veterinary use, food, drugs, cosmetics, household use, or self-administration.
Catalog navigation
Other catalog records grouped under the same editorial collection.
Product inquiries
Contact Lone Star Peptide Co. for product information and inquiries.
Email to inquireRequired notice
For laboratory research use only. Not for human or veterinary use, food, drugs, cosmetics, household use, or self-administration. Product information is provided for material identification, handling, and analytical documentation; it is not medical advice or a statement of clinical safety or effectiveness.